Dr. David Scott is Deputy Head at Department of Lymphoid Cancer Research, Clinical Director at Centre for Lymphoid Cancer and Associate Professor at Faculty of Medicine, University of British Columbia.
Dr. Scott’s lab focuses on discovery and development of clinically relevant biomarkers to improve disease classification and patient care. Dr. Scott is a member of the Lymphoma/Leukemia Molecular Profiling Project Consortium and is leading a large international project along with distinguished lymphoma clinicians and experts in Cancer Genomics to uncover lymphoma pathogenesis and genomic mechanisms underlying treatment failure in aggressive lymphoma. Also, Dr. Scott is co-leading a large scale applied research project funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to address the most significant knowledge gap in lymphoma care; the genome biology of relapsed lymphoid cancers. Dr. Scott has a strong track record of discovery of biomarkers applicable to aggressive B-cell lymphomas and is recognized as an expert in biomarkers and the tumor microenvironment of these diseases. Dr. Scott has developed prognostic and predictive biomarker assays and filed four patents to date, which reflects the true translational nature of his research.


University of British Columbia, Lymphoma/Leukemia Molecular Profiling Project Consortium, Lunenburg Lymphoma Biomarker Consortium


Overcoming Treatment Failure in Lymphoid Cancer (TFRI-funded Program)

This team grant is a collaborative effort, which experts in lymphoid cancer biomarkers and tumor microenvironment, hematology and cancer genomics jointly aim to understand and overcome treatment failure in lymphoid cancers. The team will identify and validate target-specific molecular tests characterizing genetic changes and molecular pathways which provide the preclinical rationale for novel drug development.

Large-Scale Applied Research Project (LSARP Program)

Dr. Steidl and Scott teams have successfully won a large-scale applied research project worth $11.9 million funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to study the genome biology of relapsed lymphoid cancers. Our large-scale, pan-Canadian study was launched last year to discover novel, actionable markers of relapsed lymphoma from which clinically relevant assays can be developed.

Back to top